Effectiveness of interferon α in mycosis fungoides therapy

Postepy Dermatologii i Alergologii

Volumn 29, Issue 1, 2012, Pages 51-55

  Sikorska, Monika ^a   Sokołowska Wojdyło, Małgorzata ^a   Kowalczyk, Anna ^a   Roszkiewicz, Jadwiga ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Interferon 2a; Mycosis fungoides; PUVA; UVB311

Indexed keywords

ALPHA INTERFERON; CYCLOSPORIN; METHOTREXATE; PREDNISONE; PSORALEN; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ARTICLE; CANCER STAGING; CASE REPORT; ERYTHRODERMA; FEMALE; HUMAN; MALE; MYCOSIS FUNGOIDES; PUVA; TREATMENT RESPONSE;

EID: 84858133324     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350: 1978-88. (Pubitemid 38580201)
2. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28: 4730-9.
3. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 2007; 33: 146-60. (Pubitemid 46323394)
4. Gardner JM, Evans KG, Musiek A, et al. Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 2009; 21: 131-7.
5. Olek-Hrab K, Osmola-Mańkowska A, Silny W, et al. Use of UVA1 in the treatment of mycosis fungoides - case report. Post Dermatol Alergol 2011; 28: 158-64.
6. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-93. (Pubitemid 32458440)
7. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003; 16: 311-21. (Pubitemid 38044675)
8. Kaye FJ, Bunn PA Jr, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784-90. (Pubitemid 20015571)
9. Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 2009; 114: 4337-53.
10. Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: immuno-pathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 2011; 64: 352-404.
11. Lai L, Hui CK, Leung N, Lau GK. Pegylated interferon alpha-2a (40 kda) in the treatment of chronic hepatitis B. Int J Nanomedicine 2006; 1: 255-62.
12. Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-64. (Pubitemid 28411130)
13. Rook AH, Heald P. The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9: 997-1010.
14. Angioli R, Sevin BU, Perras JP, et al. In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines. Cancer 1993; 71: 3717-25. (Pubitemid 23152689)
15. Bunn PA Jr, Foon KA, Ihde DC, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984; 101: 484-7. (Pubitemid 14018043)
16. Ross C, Tingsgaard P, Jørgensen H, Vejlsgaard GL. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 1993; 51: 63-72. (Pubitemid 23287806)
17. Bunn PA Jr, Hoffman SJ, Norris D, et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994; 121: 592-602.
18. Chiarion-Sileni V, Bononi A, Fornasa CV, et al. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 2002; 95: 569-75. (Pubitemid 34810182)
19. Rupoli S, Goteri G, Pulini S, et al. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol 2005; 75: 136-45. (Pubitemid 41008284)
20. Bunn PA Jr, Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986; 57: 1689-95. (Pubitemid 16114319)
21. Kuzel TM, Roenigk HH, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995; 13: 257-63.
22. Knobler RM, Trautinger F, Radaszkiewicz T, et al. Treatment of cutaneous T cell lymphoma with a combination of lowdose interferon alfa-2b and retinoids. J Am Acad Dermatol 1991; 24: 247-52.
23. Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous t-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 2002; 138: 1054-60. (Pubitemid 34875609)
24. Kuzel TM, Gilyon K, Springer E, et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82: 203-7. (Pubitemid 20079991)
25. Roenigk HH Jr, Kuzel TM, Skoutelis AP, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous t-cell lymphoma. J Invest Dermatol 1990; 95 (6 Suppl): 198S-205S.
26. Mostow EN, Neckel SL, Oberhelman L, et al. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 1993; 129: 747-52. (Pubitemid 23172779)
27. Nikolaou V, Siakantaris MP, Vassilakopoulos TP, et al. PUVA plus interferon alpha2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series. J Eur Acad Dermatol Venereol 2011; 25: 354-7.
28. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-81. (Pubitemid 28525182)
29. Baron S, Tyring SK, Fleischmann WR Jr, et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266: 1375-83.
30. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: longterm survival in 489 patients. J Am Acad Dermatol 1999; 40: 418-25. (Pubitemid 29115302)
31. Małgorzata SW, Ewa LM, Waldemar P, et al. Leczenie pierwotnych chłoniaków skóry. Rekomendacje sekcji chł oniaków skóry Polskiej Grupy Badawczej Chłoniaków (PLRG). Onkol Prakt Klin 2010; 6: 29-47.